Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.21 EUR | -5.69% | -8.96% | +80.93% |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
May. 08 | NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+80.93% | 1.82B | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Prices $175.3 Million Public Offering